Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.

ABSTRACT:

Aims

Studies in cardiogenic shock (CS) often have a heterogeneous population of patients, including those with acute myocardial infarction and acute decompensated heart failure (ADHF-CS). The therapeutic profile of milrinone may benefit patients with ADHF-CS. We compared the outcomes and haemodynamic trends in ADHF-CS receiving either milrinone or dobutamine.

Methods and results

Patients presenting with ADHF-CS (from 2014 to 2020) treated with a single inodilator (milrinone or dobutamine) were included in this study. Clinical characteristics, outcomes, and haemodynamic parameters were collected. The primary endpoint was 30 day mortality, with censoring at the time of transplant or left ventricular assist device implantation. A total of 573 patients were included, of which 36

SUBMITTER: Rodenas-Alesina E 

PROVIDER: S-EPMC10375068 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature